Safety and Effectiveness of Disposable Pulmonary Surgical Markers in the Localization of Pulmonary Nodules

NCT ID: NCT04139408

Last Updated: 2021-05-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

76 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-22

Study Completion Date

2021-01-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

During the VATS procedure, some pulmonary nodules are relatively small or far away from the pleura, resulting that they are difficult to be accurately located during the procedure.

The aim of this study is to evaluate the efficacy and safety of using disposable pulmonary surgical markers to localize pulmonary nodules in subjects prior to the resection of pulmonary nodules by video-assisted thoracoscopic surgery (VATS).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is a prospective, multicenter, single group target value clinical trial. The subjects will undergo VATS within 24h after the placement of the Marker, then the Marker and targeted nodule will be removed during VATS. Subjects will be followed up intraoperatively, immediately after placement procedure to the end of VATS resection, 7 days after placement procedure/before discharge (whichever occurs earlier), and 30 days after Marker placement procedure. Demographic and baseline information of subjects, immediate operation success rate of marker placement, positioning success rate, and adverse events will be collected and recorded in this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Disposable Pulmonary Surgical Marker

Locate the pulmonary nodules with Disposable Pulmonary Surgical Marker before VATS.

Group Type EXPERIMENTAL

Disposable Pulmonary Surgical Marker

Intervention Type DEVICE

The subjects will undergo Marker placement procedure, within 24h before VATS.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Disposable Pulmonary Surgical Marker

The subjects will undergo Marker placement procedure, within 24h before VATS.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-70 years old;
* Pulmonary nodule, which satisfying any of the following Criteria:

* solid nodules with diameter ≤1 cm or solid component ≤1 cm non-purely ground glass, and the distance between the solid component of the nodule and the visceral pleural\>0.5cm;
* Pure ground glass opacity (pGGO);
* Before VATS operation, the doctor judge that the nodule is difficult to locate during the operation.
* Pulmonary wedge resection or Segmental pulmonary resection under VATS is proposed;
* Preoperative evaluation shows that placing marker through bronchus is feasible;
* The subject is able to fully understand the requirements of clinical research;
* Subject or the legal representative signs the informed consent form.

Exclusion Criteria

* Contraindications for bronchoscopy;
* Systemic factors: sepsis, history of repeated pulmonary infections, and any type of severe infectious disease within one month of screening;
* Severe cardio and pulmonary disease;
* Coagulation dysfunction, with a clear tendency to bleed;
* General anesthesia contraindication;
* Allergic history of nickel-titanium materials;
* Breast-feeding or may be or plan to be pregnant during the trial;
* Participating in clinical trials of other drugs or medical devices;
* Other conditions that Investigator consider the subject to be inappropriate.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hangzhou Broncus Medical Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bin Qiu, MD

Role: PRINCIPAL_INVESTIGATOR

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, , China

Site Status

Yunnan Cancer Hospital

Kunming, , China

Site Status

Cancer Hospital of Chinese Academy of Medical Sciences,Shenzhen Center

Shenzhen, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BC-HM-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pulmonary Nodule Cohort
NCT04049422 NOT_YET_RECRUITING